



Do you or someone you know have Type 1 Diabetes?

Dr. Qin Yang at the University of California, Irvine is conducting a clinical trial to find out if the VC-02 Combination Product can control blood sugar by producing insulin after it is surgically placed.

Patients will be screened for safety and eligibility through a review of their medical history, physical assessments and blood tests. Eligible patients will be surgically implanted with the VC-02 Combination Product and will be evaluated for up to 24 months on the effectiveness, safety and tolerability of VC-02 through follow-up visits over the following two years. VC-02 is intended to control blood sugar as a “replacement pancreas”, producing insulin within several months of being implanted.

Main Inclusion Criteria

- ◆ Adults, ages 18-65 years of age
- ◆ Have had a diagnosis of T1DM for a minimum of 5 years
- ◆ Are on a stable insulin regimen for at least 3 months
- ◆ Have documented hypoglycemia unawareness or significant glycemic lability
- ◆ Had at least one hypoglycemic event in the past year
- ◆ Be willing to be on chronic immunosuppression for the duration of the study

Benefits

Taking part in this study may or may not make your health better. While researchers hope VC-02 will be more effective than the standard (usual) treatment, there is no proof of this yet. This study will help researchers learn more about VC-02 as a potential treatment for Type 1 Diabetes, and it is hoped that this information will help in the treatment of future patients with this condition.

Expected Duration

If you decide to participate and meet the requirements to enroll, your involvement will last approximately 2 years. You will complete a total of about 18 study visits.

If you are interested, please contact:

UC Irvine Alpha Stem Cell Clinic

949-824-3990

islet@uci.edu

Where is the study conducted?

At the UC Irvine Gottschalk Medical Plaza in Irvine, CA and
the UC Irvine Medical Center in Orange, CA.